--- title: "BrightSpring Health Services - Unit | 8-K: FY2026 Q2 Revenue: USD 3.873 B" type: "News" locale: "en" url: "https://longbridge.com/en/news/294494994.md" datetime: "2026-07-31T10:10:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294494994.md) - [en](https://longbridge.com/en/news/294494994.md) - [zh-HK](https://longbridge.com/zh-HK/news/294494994.md) --- # BrightSpring Health Services - Unit | 8-K: FY2026 Q2 Revenue: USD 3.873 B Revenue: As of FY2026 Q2, the actual value is USD 3.873 B. EPS: As of FY2026 Q2, the actual value is USD 0.38. EBIT: As of FY2026 Q2, the actual value is USD 130.39 M. ### Second Quarter 2026 Financial Highlights (Continuing Operations) - Net Income: $84,209 thousand, compared to $27,542 thousand in the second quarter of 2025. - Adjusted EBITDA: $205,505 thousand, an increase of 44% from $142,517 thousand in the second quarter of 2025. - Leverage: 2.15x as of June 30, 2026, down from 2.27x on March 31, 2026. - Debt Actions: BrightSpring Health Services, Inc. included a $300.0 million paydown and modification of the First Lien Facility, which led to interest savings. - Share Repurchase: The company repurchased 1,026,465 shares of common stock for $60.0 million in June 2026. ### Segment Performance #### Three Months Ended June 30, 2026 vs. 2025 - Pharmacy Solutions segment EBITDA: $180 million in 2026, up 44% from $125 million in 2025. - Provider Services segment EBITDA: $75 million in 2026, up 33% from $56 million in 2025. - Total Segment Adjusted EBITDA: $255 million in 2026, up 41% from $181 million in 2025. - Corporate Costs: - $49 million in 2026, compared to - $39 million in 2025. - Total Company Adjusted EBITDA: $206 million in 2026, up 44% from $143 million in 2025. #### Six Months Ended June 30, 2026 vs. 2025 - Pharmacy Solutions segment EBITDA: $349 million in 2026, up 45% from $240 million in 2025. - Provider Services segment EBITDA: $141 million in 2026, up 31% from $108 million in 2025. - Total Segment Adjusted EBITDA: $490 million in 2026, up 41% from $348 million in 2025. - Corporate Costs: - $95 million in 2026, compared to - $74 million in 2025. - Total Company Adjusted EBITDA: $395 million in 2026, up 45% from $274 million in 2025. ### Operational Metrics #### Three Months Ended June 30, 2026 vs. 2025 - Pharmacy Solutions Prescriptions dispensed: 10,844,038 in 2026, a 0% change from 10,851,773 in 2025. - Pharmacy Solutions Revenue per script: $314.20 in 2026, up 22% from $257.11 in 2025. - Pharmacy Solutions Gross Profit per script: $27.50 in 2026, up 28% from $21.54 in 2025. - Provider Services Home Health Care average daily census: 46,448 in 2026, up 54% from 30,085 in 2025. - Provider Services Rehab Care persons served: 7,755 in 2026, up 9% from 7,119 in 2025. - Provider Services Personal Care persons served: 16,357 in 2026, up 1% from 16,138 in 2025. #### Six Months Ended June 30, 2026 vs. 2025 - Pharmacy Solutions Prescriptions dispensed: 21,573,914 in 2026, a -1% change from 21,729,067 in 2025. - Pharmacy Solutions Revenue per script: $304.93 in 2026, up 25% from $244.94 in 2025. - Pharmacy Solutions Gross Profit per script: $27.76 in 2026, up 38% from $20.14 in 2025. - Provider Services Home Health Care average daily census: 46,258 in 2026, up 53% from 30,163 in 2025. - Provider Services Rehab Care persons served: 7,688 in 2026, up 11% from 6,909 in 2025. - Provider Services Personal Care persons served: 16,219 in 2026, up 1% from 16,001 in 2025. ### Operating Costs and Profit #### Three Months Ended June 30, 2026 vs. 2025 (in thousands) - Cost of goods: $3,108,992 in 2026 vs. $2,556,402 in 2025. - Cost of services: $271,402 in 2026 vs. $216,444 in 2025. - Selling, general, and administrative expenses: $362,355 in 2026 vs. $326,295 in 2025. - Operating income: $130,391 in 2026 vs. $48,557 in 2025. - Interest expense, net: $36,879 in 2026 vs. $38,778 in 2025. - Income from continuing operations before income taxes: $93,512 in 2026 vs. $9,779 in 2025. - Income tax expense: $6,908 in 2026 vs. $1,238 in 2025. - (Loss) income from discontinued operations, net of income taxes: - $2,395 in 2026 vs. $19,001 in 2025. - Net income attributable to BrightSpring Health Services, Inc. and subsidiaries: $84,290 in 2026 vs. $28,208 in 2025. #### Six Months Ended June 30, 2026 vs. 2025 (in thousands) - Cost of goods: $5,979,567 in 2026 vs. $4,884,617 in 2025. - Cost of services: $532,326 in 2026 vs. $427,989 in 2025. - Selling, general, and administrative expenses: $723,128 in 2026 vs. $613,925 in 2025. - Operating income: $251,840 in 2026 vs. $99,296 in 2025. - Interest expense, net: $75,494 in 2026 vs. $80,541 in 2025. - Income from continuing operations before income taxes: $176,346 in 2026 vs. $18,755 in 2025. - Income tax expense: $15,459 in 2026 vs. $998 in 2025. - (Loss) income from discontinued operations, net of income taxes: $71,932 in 2026 vs. $38,795 in 2025. - Net income attributable to BrightSpring Health Services, Inc. and subsidiaries: $233,057 in 2026 vs. $57,750 in 2025. ### Cash Flow #### Three Months Ended June 30, 2026 vs. 2025 (in thousands) - Net cash provided by operating activities: $43,916 in 2026 vs. $49,076 in 2025. - Net cash used in investing activities: - $28,198 in 2026 vs. - $23,243 in 2025. - Net cash used in financing activities: - $354,134 in 2026 vs. - $8,243 in 2025. - Cash and cash equivalents at end of period: $550,381 in 2026 vs. $70,232 in 2025. #### Six Months Ended June 30, 2026 vs. 2025 (in thousands) - Net cash provided by operating activities: $166,859 in 2026 vs. $150,674 in 2025. - Net cash provided by investing activities: $719,195 in 2026 vs. - $47,434 in 2025. - Net cash used in financing activities: - $424,150 in 2026 vs. - $94,261 in 2025. - Cash and cash equivalents at end of period: $550,381 in 2026 vs. $70,232 in 2025. ### Full Year 2026 Financial Guidance BrightSpring Health Services, Inc. increased its full year 2026 Revenue and Adjusted EBITDA guidance, excluding the Community Living business and future closed acquisitions. Total revenues are projected to be $15,100 million to $15,425 million, representing 17.0% to 19.5% growth compared to full year 2025, while total Adjusted EBITDA is expected to be $820 million to $845 million, indicating 32.8% to 36.8% growth. The Amedisys and LHC branches acquisition is anticipated to contribute approximately $35 million in Adjusted EBITDA in 2026. ### Related Stocks - [BTSGU.US](https://longbridge.com/en/quote/BTSGU.US.md) ## Related News & Research - [Gran Tierra Energy amends 8-K to file share sale and purchase agreement exhibit](https://longbridge.com/en/news/295388778.md) - [AQST: Q2 2026 revenue up 38% to $13.8M; Anaphylm NDA resubmission on track for Q3 2026](https://longbridge.com/en/news/295573837.md) - [Yum Brands amends 8-K to add Kathleen Oberg to audit committee](https://longbridge.com/en/news/295272677.md) - [Apollo amends 8-K to set annual say-on-pay votes starting in 2027](https://longbridge.com/en/news/295704566.md) - [Navient announces Form 8-K filing for Q2 2026 financial results](https://longbridge.com/en/news/295144488.md)